[1]国家肾脏疾病临床医学研究中心.中国慢性肾脏病矿物质和骨异常诊治指南概要[J].肾脏病与透析肾移植杂志, 2019, 28(01):52-57
[2]Ruospo M, Palmer SC, Natale P, et al.Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)[J].The Cochrane database of systematic reviews, 2018, 8(8):C-D006023
[3]Da J, Xie X, Wolf M, et al.Serum Phosphorus and Progression of CKD and Mortality: A Meta-analysis of Cohort Studies[J].Am J Kidney Dis, 2015, 66(2):258-65
[4]Goyal R, Jialal I.Hyperphosphatemia [M]. StatPearls. Treasure Island (FL); StatPearls Publishing Copyright ? 2021, StatPearls Publishing LLC. 2021.
[5]Zoccali C, Ruggenenti P, Perna A, et al.Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition[J].J Am Soc Nephrol, 2011, 22(10):1923-30
[6]Zhou C, Wang F, Wang JW, et al.Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease[J].Chin Med J (Engl), 2016, 129(19):2275-80
[7]Eddington H, Hoefield R, Sinha S, et al.Serum phosphate and mortality in patients with chronic kidney disease[J].Clinical journal of the American Society of Nephrology : CJASN, 2010, 5(12):2251-7
[8]Li J, Wang L, Han M, et al.The role of phosphate-containing medications and low dietary phosphorus-protein ratio in reducing intestinal phosphorus load in patients with chronic kidney disease[J].Nutrition & diabetes, 2019, 9(1):14-
[9]Rastogi A, Bhatt N, Rossetti S, et al.Management of Hyperphosphatemia in End-Stage Renal Disease: A New Paradigm[J].J Ren Nutr, 2021, 31(1):21-34
[10]Ketteler M, Block GA, Evenepoel P, et al.Diagnosis,Evaluation,Prevention,and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update[J].Ann Intern Med, 2018, 168(6):422-30
[11]Gattineni J, Friedman PA.Regulation of hormone-sensitive renal phosphate transport[J][J].Vitam Horm, 2015, 98:249-306
[12]Takashi Y, Fukumoto S.Phosphate-sensing and regulatory mechanism of FGF23 production[J].J Endocrinol Invest, 2020, 43(7):877-83
[13]Centeno PP, Herberger A, Mun HC, et al.Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion[J].Nat Commun, 2019, 10(1):4693-
[14]Ide N, Ye R, Courbebaisse M, et al.In vivo evidence for an interplay of FGF23KlothoPTH axis on the phosphate handling in renal proximal tubules[J].Am J Physiol Renal Physiol, 2018, 315(5):F1261-f70
[15]Mace ML, Olgaard K, Lewin E.New Aspects of the Kidney in the Regulation of Fibroblast Growth Factor 23 (FGF23) and Mineral Homeostasis[J].International journal of molecular sciences, 2020, 21(22):8810-
[16]Kido S, Kaneko I, Tatsumi S, et al.Vitamin D and type II sodium-dependent phosphate cotransporters[J][J].Contrib Nephrol, 2013, 180:86-97
[17]Leung EKY.Parathyroid hormone[J].[J].Adv Clin Chem, 2021, 101:41-93
[18]Isakova T, Wahl P, Vargas GS, et al.Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease[J].Kidney international, 2011, 79(12):1370-8
[19]石敏, 周莉, 付平.慢性肾脏病高磷血症肾损伤机制的研究进展[J].中国中西医结合肾病杂志, 2016, 17(01):76-8
[20]Hu W, Jiang S, Liao Y, et al.High phosphate impairs arterial endothelial function through AMPK-related pathways in mouse resistance arteries[J].Acta Physiol (Oxf), 2021, 231(4):e13595-
[21]Papadimitriou A, Peixoto EB, Silva KC, et al.Inactivation of AMPK mediates high phosphate-induced extracellular matrix accumulation via NOX4TGF?-1 signaling in human mesangial cells[J].Cell Physiol Biochem, 2014, 34(4):1260-72
[22]Kawakami T, Mimura I, Shoji K, et al.Hypoxia and fibrosis in chronic kidney disease: crossing at pericytes[J].Kidney Int Suppl, 2014, 4(1):107-12
[23]Nangaku M.Hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure[J].Nephron Exp Nephrol, 2004, 98(1):e8-12
[24]Zhou C, Shi Z, Ouyang N, et al.Hyperphosphatemia and Cardiovascular Disease[J].[J].Front Cell Dev Biol, 2021, 9:644363-
[25]Zhang D, Bi X, Liu Y, et al.High Phosphate-Induced Calcification of Vascular Smooth Muscle Cells is Associated with the TLR4NF-κb Signaling Pathway[J].Kidney Blood Press Res, 2017, 42(6):1205-15
[26]Liu L, Liu Y, Zhang Y, et al.High phosphate-induced downregulation of PPARγ contributes to CKD-associated vascular calcification[J].[J].J Mol Cell Cardiol, 2018, 11:264-275
[27]Zhou C, He Q, Gan H, et al.Hyperphosphatemia in chronic kidney disease exacerbates atherosclerosis via a mannosidases-mediated complex-type conversion of SCAP N-glycans[J].Kidney international, 2021, 99(6):1342-53
[28]Stevens KK, Denby L, Patel RK, et al.Deleterious effects of phosphate on vascular and endothelial function via disruption to the nitric oxide pathway[J].Nephrol Dial Transplant, 2017, 32(10):1617-27
[29]Asenjo-Bueno A, Alcalde-Estévez E, El Assar M, et al.Hyperphosphatemia-Induced Oxidant/Antioxidant Imbalance Impairs Vascular Relaxation and Induces Inflammation and Fibrosis in Old Mice[J]. [J].Antioxidants (Basel), 2021, 10(8):-
[30]Bhadada SK, Rao SD.Role of Phosphate in Biomineralization[J].Calcif Tissue Int, 2021, 108(1):32-40
[31]Ahmed S, O' Neill KD, Hood AF, et al.Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells[J].Am J Kidney Dis, 2001, 37(6):1267-76
[32]Colboc H, Moguelet P, Bazin D, et al.Localization,Morphologic Features,and Chemical Composition of Calciphylaxis-Related Skin Deposits in Patients With Calcific Uremic Arteriolopathy[J].JAMA Dermatol, 2019, 155(7):789-96
[33]黄东黎, 李莹.钙化防御与高磷血症的相关性及治疗进展[J].中国医药科学, 2020, 10(08):28-32
[34]Kwon YE, Choi HY, Kim S, et al.Fracture risk in chronic kidney disease: A Korean population-based cohort study[J].Kidney Res Clin Pract, 2019, 38(2):220-8
[35]Chung LH, Liu ST, Huang SM, et al.High phosphate induces skeletal muscle atrophy and suppresses myogenic differentiation by increasing oxidative stress and activating Nrf2 signaling[J].Aging (Albany NY), 2020, 12(21):21446-68
[36]Zhang YY, Yang M, Bao JF, et al.Phosphate stimulates myotube atrophy through autophagy activation: evidence of hyperphosphatemia contributing to skeletal muscle wasting in chronic kidney disease[J].BMC Nephrol, 2018, 19(1):45-
[37].KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)[J][J].Kidney Int Suppl,, 2009, (113):S1-S130
[38]王莉, 李贵森, 刘志红.中华医学会肾脏病学分会《慢性肾脏病矿物质和骨异常诊治指导》[J]. [J].肾脏病与透析肾移植杂志, 2013, 6:6-
[39]国家肾脏疾病临床医学研究中心.中国慢性肾脏病矿物质和骨异常诊治指南概要[J].肾脏病与透析肾移植杂志, 2019, 28(1):6-
[40]Tentori F, Blayney MJ, Albert JM, et al.Mortality risk for dialysis patients with different levels of serum calcium,phosphorus,and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)[J].Am J Kidney Dis, 2008, 52(3):519-30
[41]Ketteler M, Brandenburg V, Jahnen-Dechent W, et al.Do not be misguided by guidelines: the calcium x phosphate product can be a Trojan horse[J].Nephrol Dial Transplant, 2005, 20(4):673-7
[42]Block GA, Wheeler DC, Persky MS, et al.Effects of phosphate binders in moderate CKD[J].J Am Soc Nephrol, 2012, 23(8):1407-15
[43]Di Iorio B, Bellasi A, Russo D.Mortality in kidney disease patients treated with phosphate binders: a randomized study[J].Clinical journal of the American Society of Nephrology : CJASN, 2012, 7(3):487-93
[44]Di Iorio B, Molony D, Bell C, et al.Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial[J].Am J Kidney Dis, 2013, 62(4):771-8
[45]Jamal SA, Vandermeer B, Raggi P, et al.Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis[J].Lancet, 2013, 382(9900):1268-77
[46]Ikizler TA, Burrowes JD, Byham-Gray LD, et al.KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update[J].Am J Kidney Dis, 2020, 76(3 Suppl 1):S1-s107
[47]Cannata-Andía JB, Martin KJ.The challenge of controlling phosphorus in chronic kidney disease[J].Nephrol Dial Transplant, 2016, 31(4):541-7
[48]Zhang L, Wang F, Wang L, et al.Prevalence of chronic kidney disease in China: a cross-sectional survey[J].Lancet, 2012, 379(9818):815-22
[49]Vikrant S, Parashar A.Prevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: A study from a tertiary care hospital in India[J].Indian J Endocrinol Metab, 2016, 20(4):460-7
[50]贾世柱.期慢性肾脏病非透析患者的钙磷代谢指标分析[J].中国实用医药, 2021, 16(10):41-4
[51]廖常志, 张静, 何强, 等.慢性肾脏病患者血清及钙磷异常的发生率[J].四川医学, 2011, 32(9):1338-40
[52]Adeney KL, Siscovick DS, Ix JH, et al.Association of serum phosphate with vascular and valvular calcification in moderate CKD[J].J Am Soc Nephrol, 2009, 20(2):381-7
[53]刘海军, 杨秀芹, 宋庆庆, 等.慢性肾脏病非透析患者发生心脏瓣膜钙化的危险因素分析[J].山东医学高等专科学校学报, 2021, 43(3):170-2
[54]Eddington H, Hoefield R, Sinha S, et al.Serum phosphate and mortality in patients with chronic kidney disease[J].Clin J Am Soc Nephrol, 2010, 5(12):2251-7
[55]陈清萍, 张丰萍, 曹珊, 等.慢性肾脏病-期非透析患者死亡的危险因素分析[J].南昌大学学报医学版, 2013, 53(12):53-5
[56]de Fornasari ML, Dos Santos Sens YA.Replacing Phosphorus-Containing Food Additives With Foods Without Additives Reduces Phosphatemia in End-Stage Renal Disease Patients: A Randomized Clinical Trial[J].J Ren Nutr, 2017, 27(2):97-105
[57]Shinaberger CS, Greenland S, Kopple JD, et al.Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?[J].Am J Clin Nutr, 2008, 88(6):1511-8
[58]London GM, Guérin AP, Marchais SJ, et al.Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality[J].Nephrol Dial Transplant, 2003, 18(9):1731-40
[59]Pennick M, Dennis K, Damment SJ.Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate[J].J Clin Pharmacol, 2006, 46(7):738-46
[60]Joy MS, Finn WF.Randomized,double-blind,placebo-controlled,dose-titration,phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia[J].Am J Kidney Dis, 2003, 42(1):96-107
[61]Guo H, Zhang X, Tang S, et al.Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate[J].Ren Fail, 2013, 35(10):1455-64
[62]Wang F, Lu X, Zhang J, et al.Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials[J].Kidney Blood Press Res, 2018, 43(2):536-44
[63]Zhang C, Wen J, Li Z, et al.Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review[J].[J].BMC Nephrol, 2013, 14:226-
[64]史明君, 谢红浪.新型磷结合剂在慢性肾脏病中的应用[J].[J].肾脏病与透析肾移植杂志, 2011, 20(6):-
[65]张佳龙, 郝峻烽, 党大胜, 等.磷结合剂治疗慢性肾病患者高磷血症[J].临床军医杂志, 2015, 43(12):1312-5
[66]Sekercioglu N, Thabane L, Díaz Martínez JP, et al.Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis[J].PLoS One, 2016, 11(6):e0156891-
[67]Liu ZH, Yu XQ, Yang JW, et al.Prevalence and risk factors for vascular calcification in Chinese patients receiving dialysis: baseline results from a prospective cohort study[J].Curr Med Res Opin, 2018, 34(8):1491-500
[68]Raggi P, Vukicevic S, Moysés RM, et al.Ten-year experience with sevelamer and calcium salts as phosphate binders[J]. [J].Clinical journal of the American Society of Nephrology : CJASN, 2010, 5:S3-S40
[69]Goh BL, Soraya A, Goh A, et al.Cost-Effectiveness Analysis for the Treatment of Hyperphosphatemia in Predialysis Patients: Calcium-Based versus Noncalcium-Based Phosphate Binders[J]. [J].Int J Nephrol,, 2018, :2138528-
[70]Hill KM, Martin BR, Wastney ME, et al.Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease[J].Kidney international, 2013, 83(5):959-66
[71]Ketteler M, Rix M, Fan S, et al.Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis[J].Clinical journal of the American Society of Nephrology : CJASN, 2008, 3(4):1125-30
[72]Vervloet MG, van Ballegooijen AJ.Prevention and treatment of hyperphosphatemia in chronic kidney disease[J].Kidney international, 2018, 93(5):1060-72
